Brenda Thompson: Daily

A Chinese startup's tiny new heart pump enters human trials, aiming to disrupt a billion-dollar market and solve a massive unmet need in cardiac care.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.

Lightbeam's new NCQA prevalidation isn't just a certificate. It's a strategic move reshaping compliance, patient outcomes, and the health tech market.

Gossamer Bio's recent 200,000-share grant to a new hire is more than a welcome bonus; it's a strategic bet on its blockbuster drug candidate.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Vapotherm partners with Flight Medical, launching the VentO2ux ventilator to challenge market giants and redefine emergency respiratory care in the US.

A South Korean biotech's novel antibody, now named rapaprutug, could shift the paradigm for pulmonary arterial hypertension by targeting its root causes.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

B. Braun's new ready-to-activate antibiotic system promises to save time, reduce errors, and streamline care. Here's how it could reshape hospital efficiency.

A major CRO presents 10 pivotal studies at the world's top blood disease meeting, revealing a strategy built on real-world data and collaborative innovation.

With new EHR integrations and a direct-to-provider model, Speke AI is making its ambient intelligence tools more accessible than ever. Is this the tipping point?

With a fresh $212M, Enlivex is not only advancing its osteoarthritis drug but also building a treasury on a crypto token. A revolutionary new model or a risky distraction?

New data reveals a stunning leap in hospital safety, saving 300,000 lives. Discover the tech and strategies behind this remarkable post-pandemic turnaround.

Nona Biosciences appoints a top AI mind to lead its A³ strategy, a bold move in the industry-wide race to automate drug discovery and outpace rivals.

Seattle-based Curi Bio secures strategic funding to scale its human-centric platforms, aiming to end the costly failures of traditional animal-based drug testing.

A new survey reveals a disconnect in menopause support, with a focus on mental health obscuring a costly metabolic crisis. Here’s why it matters.

A new AI platform is creating digital replicas of every clinical trial site, promising to slash drug development timelines and costs. Here's how.

Evestia Clinical's new advisory board is a bold move to dominate specialized CRO markets by combining deep therapeutic expertise with AI and global reach.